Home / Investments

Investments

Devon Energy, WPX to Merge in All-Stock Deal

The shale drillers are combining in an all-stock merger of equals, creating an entity with a combined market value of about $6 billion. The move could help them weather the prolonged slump in oil demand amid the Covid-19 pandemic

Read More »

Inflation Is Already Here—For the Stuff You Actually Want to Buy

Prices are rising for things people need in the pandemic, even if the overall inflation number remains subdued

Read More »

CarMax Only Looks Like a Lemon

The used-car retailer is clearly hyper-aware of budding online competitors such as Carvana; so are its investors.

Read More »

U.S. Stocks End Higher as S&P 500 Snaps Losing Streak

The recovery follows a bout of volatility that has tested investors’ confidence in the market’s monthslong rebound.

Read More »

HSBC Stock Hits 25-Year Low

Shares in HSBC slumped after news articles detailed “suspicious activity reports” filed by it and other major banks to U.S. authorities, putting fresh pressure on a stock that has already dropped sharply this year.

Read More »

How to Think Long Term With Near-Zero Rates

America’s savers and borrowers face possibly harder choices than they did in the previous recession. Here are key considerations.

Read More »

Steve Cohen's Point72 Settles With Female Employee in Gender Discrimination Arbitration

Steven A. Cohen’s Point72 Asset Management recently reached a settlement with a female employee who sued the firm in 2018 alleging unfair pay practices and a pervasively sexist work environment.

Read More »

Alibaba-Backed Courier to List in Hong Kong

ZTO Express plans to raise up to $1.56 billion, becoming the latest Chinese company to seek a secondary listing in Hong Kong as tensions between the U.S. and China rise.

Read More »

'Real' Bond Yields Help Explain Market Moves

Negative inflation-adjusted government bond yields encourage investors to keep taking risks, even after the recent tech-led selloff in stocks.

Read More »

Gilead Nears Deal to Buy Immunomedics for More Than $20 Billion

The biotech drugmaker has a market value of roughly $10 billion, meaning that Gilead would be paying up for the company and its prized breast-cancer drug.

Read More »
css.php
Font Resize